Why do microbleeds occur predominantly in cortical layers 4-5 while CAA affects layers 1-2?

OPEN

The study reveals a striking anatomical dissociation between microbleed locations (layers 4-5) and cerebral amyloid angiopathy (layers 1-2), discounting CAA as the cause of MBs. The underlying vascular or cellular differences driving this layer-specific vulnerability are unknown. Gap type: unexplained_observation Source paper: Age, sex, and cerebral microbleeds in EFAD Alzheimer disease mice. (2021, Neurobiology of aging, PMID:33813349)

Priority: 0.75 Domain: cerebrovascular-pathology Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: Why do microbleeds occur predominantly in cortical layers 4-5 while CAA affects layers 1-2? is a 0.75 priority gap in cerebrovascular-pathology. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Why do microbleeds occur predominantly in cortical layers 4-5 while CAA affects layers 1-2? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

associated with (1)

CAAcognitive decline

causes (5)

APOECAAapoE4CAAVSMC dysfunctionCAACAAtraumatic microhemorrhage burdenCAAVSMC degeneration

co associated with (1)

ABCA1CAA

increases risk (2)

APOECAAapoE4CAA

increases risk of (1)

APOE_e4CAA

prevents (1)

VSMC-mediated Aβ clearanceCAA

prevents complete normalization of (1)

CAACSF_p-tau217

targets (2)

ApoE-Aβ axisCAAanti-amyloid antibodiesCAA
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps